Targeted therapies, including CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors, such as PI3K inhibitors (e.g., alpelisib) have been approved for treating endocrine-resistant ER+ breast cancer, particularly in PIK3CA-mutated cases. Here, AKT1 is linked to breast carcinoma.